D
ronedarone is a new antiarrhythmic agent that is used to restore sinus rhythm and to reduce rates of hospitalization for cardiovascular causes in patients with intermittent (paroxysmal or persistent) atrial fibrillation. 1 In ATHENA (A Placebo-Controlled, DoubleBlind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400 mg bid for the Prevention of Cardiovascular Hospitalization or Death from any Cause in Patients with Atrial Fibrillation/Atrial Flutter; ClinicalTrials.gov number, NCT00174785), 4628 patients with intermittent atrial fibrillation were randomly assigned to receive either dro neda rone or placebo. Dronedarone reduced the incidence of the primary outcome of unplanned hospitalization for cardiovascular causes or death. Significant reductions in rates of death from cardiovascular causes, stroke, and hospitalization for acute coronary syndrome were also seen. 2, 3 We decided to evaluate dro ne da rone in patients with permanent atrial fibrillation because such patients are at high risk for cardiovascular events of the type that had been reduced in frequency in ATHENA. 4, 5 The treatment effects of dro neda rone in ATHENA had been seen in most subgroups of patients, including those in whom permanent atrial fibrillation developed during the study, 6 which suggested that restoration of sinus rhythm may not be the only mechanism of benefit associated with this drug. Dronedarone has other effects that would be potentially beneficial in patients with permanent atrial fibrillation, including slowing of the heart rate during atrial fibrillation, 7 blood-pressure lowering, 2 and adrenergic blockade. 8, 9 In addition, dro ne da rone has been shown to suppress ventricular fibrillation in animal models 10, 11 and significantly reduced the rate of death from arrhythmia in ATHENA. 2 PALLAS (Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy) was designed to test whether dro ne darone would reduce rates of major vascular events or unplanned hospitalization for cardiovascular causes in patients with permanent atrial fibrillation who were at high risk for vascular events.
Me thods

Study Conduct
This study was a randomized, double-blind, placebo-controlled trial conducted at 489 sites in 37 countries. The trial was sponsored by SanofiAventis and was approved by the ethics committee at each participating center. It was led by operations and steering committees, whose members jointly designed the study and decided to submit the manuscript for publication. The Population Health Research Institute in Hamilton, Ontario, Canada, gathered and analyzed the data. The first author wrote the manuscript and vouches for the completeness and accuracy of the data and the analyses and for the fidelity of this report to the trial protocol, which is available with the full text of this article at NEJM.org.
Study Population
We enrolled patients with permanent atrial fibrillation or flutter, as documented on electrocardiography performed both within 14 days before randomization and 6 or more months beforehand, who had no evidence of intervening sinus rhythm and for whom there was no plan to restore sinus rhythm. Eligible patients were at least 65 years of age with at least one of the following risk factors: coronary artery disease; previous stroke or transient ischemic attack; symptomatic heart failure, which was defined as current New York Heart Association class II or III symptoms and admission to the hospital for heart failure in the previous year (but not in the most recent month); a left ventricular ejection fraction of 40% or less; peripheral arterial disease; or the combination of an age of 75 years or older, hypertension, and diabetes. Major exclusion criteria were paroxysmal or persistent atrial fibrillation, use of an implantable cardioverter-defibrillator, sustained daytime bradycardia of less than 50 beats per minute, or a QT interval corrected for heart rate of more than 500 msec (or >530 msec for patients with a paced ventricular rhythm). All patients provided written informed consent.
Study Design
Eligible patients were randomly assigned to receive either dro ne da rone (at a dose of 400 mg twice daily) or matching placebo. Patients were seen on days 7 and 30, at 4 months, and every 4 months thereafter. Investigators were advised to use digoxin with caution and to monitor serum levels closely. The serum level of digoxin was measured on day 7. Drugs that are known to prolong the QT interval were prohibited. Liver-function tests (measurements of alanine aminotransferase and bilirubin levels) were initially performed at each study office visit; after a protocol amendment in Janu- ary 2011, these tests were performed monthly in the first 6 months and every 2 months for the remainder of the first year.
Study Outcomes
The first coprimary outcome was a composite of stroke, myocardial infarction, systemic embolism, or death from cardiovascular causes. The second coprimary outcome was unplanned hospitalization for a cardiovascular cause or death. Other outcomes were death from cardiovascular causes, death from arrhythmia, recurrent hospitalization for cardiovascular causes, total nights in the hospital for cardiovascular reasons, acute coronary syndrome, stroke or systemic embolism, hospitalization for heart failure or heart-failure episode without hospitalization, and death from any cause. Death from cardiovascular causes included deaths associated with arrhythmia and those caused by heart failure, stroke, and other vascular events.
Deaths from arrhythmia included unwitnessed deaths occurring without symptoms or previous hemodynamic decompensation. The diagnosis of myocardial infarction was based on a characteristic rise and fall in cardiac biomarkers with other evidence of myocardial ischemia. Stroke was defined as the rapid onset of a new, persistent neurologic deficit attributable to an obstruction in cerebral blood flow or hemorrhage and was classified as ischemic, hemorrhagic, or unspecified. Unplanned cardiovascular hospitalization was defined as nonelective hospitalization for a specified cardiovascular reason for at least two consecutive dates (overnight) or a prolongation of a noncardiovascular hospitalization for cardiovascular reasons. Heart-failure episodes (without hospitalization) were defined as new or worsening signs or symptoms of heart failure requiring intensification of heart-failure treatment. All primary and secondary outcomes (except heart-failure episodes) were adjudicated by an expert committee whose members were unaware of study-group assignments.
Statistical Analysis
Assuming an event rate of 4.5% in the control group for the first coprimary outcome at 1 year, we estimated that an enrollment of 10,800 patients during a 2-year period with 1 year of additional follow-up would result in the occurrence of 844 events. We calculated that this sample size would provide a power of 90% to detect a relative reduction of 20% in the rate of the first coprimary outcome. The primary analysis was based on a log-rank test with a two-sided alpha level of 0.05. A Holm's procedure was planned to control for multiple statistical comparisons. Student's t-test and the chi-square test were used for the evaluation of continuous and categorical variables, respectively. For patients receiving anticoagulation therapy, we calculated the time in the therapeutic range using linear interpolation of values for the international normalized ratio (INR) over time. A data monitoring committee was charged with recommending termination of the study for safety reasons in the case of clear, consistent, and persistent evidence of net harm that overwhelmed benefit. One scheduled interim analysis for efficacy was planned when 50% of expected events had occurred, on the basis of a modified Haybittle-Peto boundary of 4 SD.
R e sult s
Patients and Follow-up
Study enrollment began on July 19, 2010. The data monitoring committee recommended on July 5, 2011 , that the study be terminated for safety reasons. A date of July 15, 2011, was specified for the end of follow-up. A total of 3236 patients had undergone randomization with median follow-up of 3.5 months. There were two patients without vitalstatus assessment at the end of the study. The two study groups were well balanced with respect to demographic and clinical characteristics (Table 1) .
Patients had a mean age of 75 years, and 69% had more than a 2-year history of permanent atrial fibrillation or flutter. About two thirds of the patients had a history of heart failure. A total of 88% of the patients were receiving rate-control medication, one third were receiving digoxin, and 84% were receiving a vitamin K antagonist ( Table 1 in the Supplementary Appendix, available at NEJM.org).
In the intention-to-treat population, the baseline electrocardiogram showed atrial fibrillation in 98% of the patients and atrial flutter in 2%. At the planned 4-month visit, sinus rhythm was present in 23 of 621 patients (3.7%) in the dro neda rone group and in 9 of 638 patients (1.4%) in the placebo group (P = 0.01). Cardioversion was attempted in 4 patients (0.2%) in the dro ne da rone group and 2 patients (0.1%) in the placebo group.
The mean (±SD) baseline heart rate was 77±16 beats per minute in the dro ne da rone group and 
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78±16 beats per minute in the placebo group. At the planned 1-month visit, the mean heart rate was reduced by 7.6±14.5 beats per minute in the dro ne da rone group and was increased by 0.1±14.0 beats per minute in the placebo group (P<0.001).
The baseline systolic blood pressure was 133±17 mm Hg in the two study groups. At 1 month, the mean reduction in systolic blood pressure was 3.5±16.1 mm Hg in the dro ne da rone group and 1.7±16.1 mm Hg in the placebo group (P = 0.003). The mean corrected QT interval (Bazett's formula) was 426±40 msec in the dro ne da rone group and 425±40 msec in the placebo group at baseline; at 1 month, the mean increase was 8±40 msec in the dro ne da rone group and 2±38 msec in the placebo group (P<0.001).
For patients receiving digoxin, the mean serum digoxin concentration on day 7 was 1.2±0.8 ng per milliliter for 447 patients in the dro ne da rone group and 0.9±0.6 ng per milliliter for 438 patients in the placebo group (P <0.001). Study medication was permanently discontinued prematurely in 348 patients (21%) in the dro ne da rone group and in 178 patients (11%) in the placebo group (P<0.001). For patients receiving a vitamin K antagonist, the mean time in the therapeutic range (INR, 2.0 to 3.0) was 55.6% in the dro ne da rone group and 58.6% in the placebo group (P = 0.02).
Outcomes
The first coprimary outcome occurred in 43 patients receiving dro ne da rone and 19 patients receiving placebo (hazard ratio in the dro ne da rone group, 2.29; 95% confidence interval [CI], 1.34 to 3.94; P = 0.002) ( Table 2 and Fig. 1 ). The second coprimary outcome occurred in 127 patients receiving dro ne da rone and 67 patients receiving placebo (hazard ratio, 1.95; 95% CI, 1.45 to 2.62; P<0.001) (Fig. 2 ). There were 25 deaths in the drone da rone group and 13 in the placebo group (hazard ratio, 1.94; 95% CI, 0.99 to 3.79; P = 0.049). There were 21 deaths from cardiovascular causes in the dro ne da rone group and 10 in the placebo group (hazard ratio, 2.11; 95% CI, 1.00 to 4.49; P = 0.046), including those associated with arrhythmia in 13 patients receiving dro ne da rone and 4 patients receiving placebo (hazard ratio, 3.26; 95% CI, 1.06 to 10.00; P = 0.03). Stroke occurred in 23 patients in the dro ne da rone group and 10 in the placebo group (hazard ratio, 2.32; 95% CI, 1.11 to 4.88; P = 0.02).
Unplanned hospitalization for cardiovascular causes occurred in 113 patients receiving dro neda rone and 59 patients receiving placebo (hazard ratio, 1.97; 95% CI, 1.44 to 2.70; P<0.001). Hospitalization for heart failure occurred in 43 patients in the dro ne da rone group and 24 in the placebo group (hazard ratio, 1.81; 95% CI, 1.10 to 2.99; P = 0.02). Hospitalization for heart failure or a * Plus-minus values are means ±SD. There were no significant differences between the two study groups. † Symptomatic heart failure was defined as current New York Heart Association class II or III symptoms and hospitalization for heart failure in the previous year (but not in the most recent month). ‡ CHADS 2 is a risk-prediction score ranging from 0 to 6 that gives 1 point each for congestive heart failure, hypertension, age of 75 years or older, and diabetes and 2 points for either stroke or transient ischemic attack. Data were missing for one patient in each study group. heart-failure episode occurred in 115 patients receiving dro ne da rone and 55 receiving placebo (hazard ratio, 2.16; 95% CI, 1.57 to 2.98; P<0.001).
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Adverse Events
The most common adverse events were diarrhea, asthenic condition, nausea and vomiting, dizziness, dyspnea, and bradycardia. An elevation of alanine aminotransferase of more than three times the upper limit of the normal range occurred in 22 of 1481 (1.5%) patients receiving dro ne da rone and in 7 of 1546 (0.5%) receiving placebo (P = 0.02) ( Table 3) .
Subgroup Analyses
To assess the consistency of the effects of dro ne darone on the two coprimary composite outcomes, prespecified and ad hoc subgroup analyses were performed according to baseline characteristics ( Fig. 1 and 2 in the Supplementary Appendix). The effects of dro ne da rone were highly consistent across subgroups. For the second coprimary outcome of unplanned hospitalization for cardiovascular causes or death, there was one significant interaction: as compared with patients without diabetes, there was a relatively greater risk associated with dro ne da rone in patients with diabetes (P = 0.03 for interaction). The risk associated with dro ne da rone was consistent for both primary outcomes and for hospitalization for heart failure, regardless of whether the left ventricular ejection fraction was 40% or lower or above 40% or whether patients had New York Heart Association class II or III symptoms.
Discussion
In this study, among patients with permanent atrial fibrillation and additional cardiovascular risk factors who received dro ne da rone, we found a highly significant doubling in the rate of the first composite coprimary outcome (stroke, myocardial infarction, systemic embolism, or death from cardiovascular causes). This increase was driven by increased rates of stroke and death from cardiovascular causes, with myocardial infarction and * The first coprimary outcome was a composite of stroke, myocardial infarction, systemic embolism, or death from cardiovascular causes. The second coprimary outcome was a composite of unplanned hospitalization for cardiovascular causes or death. NA denotes not applicable. † Hazard ratios are for the comparison between the dronedarone group and the placebo group. ‡ The types of five strokes (four in the dronedarone group and one in the placebo group) were not specified, and one stroke in the dronedarone group was hemorrhagic. § This category includes two patients who died from reported heart failure. 
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systemic embolism occurring at very low rates. We also found an increase in rates of heart failure in the dro ne da rone group. The increased rates of stroke, death from cardiovascular causes, and heart failure explain, to a considerable extent, the highly significant near doubling in the rate of the second coprimary outcome (unplanned hospitalization for cardiovascular causes or death). The early trial termination markedly reduced the statistical power of the study. Early termination also increases uncertainty about the interpretation of the P values, and the point estimate of the hazard ratio is potentially biased away from the null. Despite these limitations, however, the assessment of net harm from dro ne da rone in patients with permanent atrial fibrillation who are at high risk appears to be sound.
In our study after 1 month, patients receiving dro ne da rone had significant net reductions of 8 beats per minute in heart rate and reductions of 3.5 mm Hg in systolic blood pressure. These physiological effects did not translate into reductions in rates of heart failure and other events, either because the changes were too small or because there were other effects that concurrently increased the risk. In dogs with healed myocardial infarction, dro ne da rone did not reduce measures of myocardial contractile function, 12 nor did it reduce the left ventricular ejection fraction in patients with compensated heart failure and an ejection fraction of less than 30%. 13 However, dro ne da rone affects the inward sodium channels in the cardiac-cell membrane, 14, 15 and other drugs with this property do reduce left ventricular contractility. 16 In ANDROMEDA (Antiarrhythmic Trial with Dro ne da rone in Moderate to Severe CHF Evaluating Morbidity Decrease, NCT00543699) involving 627 patients with heart failure and severe left ventricular systolic dysfunction, 17 dro ne da rone increased mortality, an effect that was largely attributed to heart failure and that suggested a negative inotropic effect of dro ne da rone. However, in ATHENA, there was a consistent decrease in rates of hospitalization for heart failure in patients with heart failure. 18 In our study, the increased risk of stroke in patients receiving dro ne da rone is unexplained. In ATHENA, there was a reduction in the rate of stroke 2 among patients receiving dro ne da rone, a finding that could be related to the prevention of recurrence of atrial fibrillation. Dronedarone interacts minimally with vitamin K antagonists, 19 and in our study, the time in the therapeutic INR range was significantly lower among patients receiving dro ne da rone. However, this effect appears to be too small to explain the large increase in the rate of stroke.
The increase in the rate of death from cardiovascular causes was mostly due to a substantial increase in the rate of death associated with arrhythmia. This finding was surprising, since dro- 
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ne da rone had not been associated with proarrhythmic toxic effects in previous studies in animals, 10, 11 and in ATHENA, dro ne da rone significantly reduced the tertiary outcome of death from arrhythmia by 45%. 2 However, dro ne da rone is a cardiac multiple ion-channel blocker, 14,15 and other cardiac ion-channel-blocking antiarrhythmic drugs have been shown to increase rates of death associated with arrhythmia. 20,21 Dronedarone increases the serum digoxin level through a P-glycoprotein interaction, 19 and digoxin toxicity is associated with life-threatening ventricular arrhythmia and conduction block. 22 In our study, almost one third of patients were receiving digoxin, and in these patients, dro ne darone increased digoxin serum levels by 33%, from 0.9 to 1.2 ng per milliliter. A post hoc analysis of the Digitalis Investigation Group (DIG) trial (NCT00000476) 23 reported that a serum digoxin level of more than 1.2 ng per milliliter was associated with a significant increase in death from cardiovascular causes not related to heart failure. It is therefore possible that digoxin toxicity induced by dro ne da rone played a role in the increased cardiovascular mortality.
Our findings regarding the effects of dro ne darone, among patients with atrial fibrillation, differed starkly from the results in ATHENA. In that trial, there was a highly significant reduction in the primary outcome of unplanned hospitalization Alanine aminotransferase >3 times ULN and bilirubin >2 times ULN 1 (<0.1) ‡ 0 NA * Listed are adverse events and serious adverse events that occurred in patients receiving at least one dose of a study drug with a reported frequency of 2% or more in each study group. The preferred term is provided for explanatory purposes in parentheses when one preferred term predominated. NA denotes not applicable, and ULN upper limit of the normal range. † Alanine aminotransferase was measured in 1481 patients in the dronedarone group and in 1546 in the placebo group; the combination of alanine aminotransferase and bilirubin was measured in 1477 patients in the dronedarone group and in 1546 in the placebo group. ‡ One patient received the diagnosis of biliary stasis that was not considered to be related to dronedarone.
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